Peptide Comparison
AHK-Cu vs Klow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
AHK-Cu has stronger documented evidence (Cosmetic Clinical Studies) than Klow (Anecdotal) while both occupy the copper-peptide class. When clinical-evidence tier is the deciding factor, AHK-Cu is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| AHK-Cu | Klow | |
|---|---|---|
| Class | Copper tripeptide (cosmetic) | Four-component regenerative blend (Glow + KPV anti-inflammatory) |
| Drug class | Dermatologic | Tissue Repair |
| Mechanism | Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp | Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. |
| Route | Topical | SC injection |
| Half-life | Topical (no systemic) | Composite: hours to days per component (TB-500 longest) |
| Dosage (research) | Topical 0.01-0.1% | Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose |
| Evidence tier | Cosmetic Clinical Studies | Anecdotal |
| Research depth | 3 indexed | — |
| Availability | Cosmetic | Compounding Restricted |
| Reported risks | Skin irritation; theoretical copper issues | No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick AHK-Cu or Klow?
AHK-Cu has stronger documented evidence (Cosmetic Clinical Studies) than Klow (Anecdotal) while both occupy the copper-peptide class. When clinical-evidence tier is the deciding factor, AHK-Cu is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between AHK-Cu and Klow?
AHK-Cu is classed as Copper tripeptide (cosmetic); Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: AHK-Cu, Topical (no systemic); Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: AHK-Cu, Topical; Klow, SC injection.
Which has stronger evidence, AHK-Cu or Klow?
AHK-Cu has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.
Which is more accessible, AHK-Cu or Klow?
Neither AHK-Cu nor Klow is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Klow, Compounding Restricted.
Are AHK-Cu and Klow ever combined?
AHK-Cu and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…